An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

NCT07482813 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Epidermolysis Bullosa (EB)

Interventions

DRUG: SD-101 Dermal Cream (6%)

Sponsor

Paradigm Therapeutics